Skip to main content

Atreca, Inc.

BCELDelisted Mar 20, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001532346

Atreca, Inc. was delisted on Mar 20, 2024; its insiders filed their last Form 4 on Apr 17, 2024; 43 institutions reported holding it in 13F filings for Q4 2023, worth $1.24M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
43
Q4 2023, −2 vs. previous quarter
13F value
$1.24M
Reported value at the end of Q4 2023
Superinvestors holding
0
At the end of Q4 2023

From SEC filings, in USD.

Revenue, FY2022
–
No comparable prior period
Net income, FY2022
-$97.2M
No comparable prior period
Free cash flow, FY2022
-$81.6M
No comparable prior period
Revenue, Q3 FY2023
–
No comparable prior period

Superinvestors holding BCEL, Q4 2023

Go to the superinvestors tab

No superinvestor reported holding BCEL at the end of Q4 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Atreca, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 17, 2024 (view filing)7:36 PM ETApr 116 daysLateOrwin John APRESIDENT & CEOPPurchaseSeries A Junior Preferred Stock+1$0.01+$0.01New position1 after
Apr 3, 2024 (view filing)9:50 PM ETApr 12 daysSerafini TitoDirectorSSaleClass A Common Stock−20.8K$0.07−$1.46K−32.3%43.6K after
Apr 3, 2024 (view filing)9:37 PM ETSep 1, 2023215 daysLateOrwin John APRESIDENT & CEOSSaleClass A Common Stock−23.0K$0.3746−$8.60K−22.8%77.5K after
Apr 3, 2024 (view filing)9:35 PM ETSep 1, 2023215 daysLateSerafini TitoDirectorSSaleClass A Common Stock−8.39K$0.3746−$3.14K−11.5%64.4K after
Apr 3, 2024 (view filing)9:33 PM ETSep 1, 2023215 daysLateCourtney PhillipsGENERAL COUNSEL & SECRETARYSSaleClass A Common Stock−7.06K$0.3746−$2.65K−12.3%50.4K after
Oct 23, 2023 (view filing)4:49 PM ETOct 194 daysBaker Julian and 3 othersOther: Former 10% OwnerSSaleClass A common stock−274.7K$0.4025−$110.6K−8.5%2.97M after2 lots
Aug 4, 2023 (view filing)Aug 22 daysSerafini TitoChief Strategy OfficerSSaleClass A Common Stock−5.49K$0.95−$5.21K−7.0%72.8K after
Aug 4, 2023 (view filing)Aug 22 daysCross HerbChief Financial OfficerSSaleClass A Common Stock−5.49K$0.95−$5.21K−7.0%72.8K after
Aug 4, 2023 (view filing)Aug 22 daysGould Stephen EChief Scientific OfficerSSaleClass A Common Stock−4.08K$0.95−$3.87K−12.5%28.4K after
Aug 4, 2023 (view filing)Aug 22 daysCourtney PhillipsGeneral Counsel & SecretarySSaleClass A Common Stock−4.08K$0.95−$3.87K−6.6%57.5K after

Top 10 13F holders, Q4 2023

See all 43 holders

The largest institutional positions in Atreca, Inc. at the end of Q4 2023; share changes are against Q3 2023.

Institutions holding BCEL in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Boxer Capital, LLC2,202,333$290.7K0.01%00.0%Unchanged
Baker Bros. Advisors LP2,177,499$287.4K0.00%−1,355,261−38.4%Reduced
Vanguard Group Inc909,300$120.0K0.00%−419,623−31.6%Reduced
Bill & Melinda Gates Foundation912,642$118.6K0.13%00.0%Unchanged
BlackRock Inc.637,974$84.2K0.00%−547,684−46.2%Reduced
Redmile Group, LLC442,653$58.4K0.00%00.0%Unchanged
Aisling Capital Management LP387,653$51.2K0.02%00.0%Unchanged
Renaissance Technologies LLC356,024$47.0K0.00%+14,100+4.1%Added
Geode Capital Management, LLC295,471$39.0K0.00%+32,548+12.4%Added
HRT Financial LP206,842$27.0K0.00%+206,842New

1 member of Congress reported 2 trades in Atreca, Inc. since 2020. Newest filings:

  1. Chris Jacobs

    House · NY · Dec 12, 2022

    Sell$1K-$15K

  2. Chris Jacobs

    House · NY · Jul 28, 2022

    Buy$15K-$50K